Realizing that all diabetics should do a periodic eye check to control their risk of Diabetic Retinopathy, Retmarker developed a technology to be used in DR Screening initiatives. The rationale is that on top of the huge number of Diabetics worldwide, on average less than 10% of them will need referral to a doctor. This means there is a huge effort to screen everyone and identify the ones in need, a burden that could benefit easily from artificial intelligence technology as everyone now accepts. 

Retmarker technology is certified as class IIa medical device in Europe and also approved in Australia. It has been tested over the years in many different conditions.

It was approved in the only independent study ever done to evaluate such technologies in real life conditions (study, led by A. Tufail from Moorfields Eye Hospital) with the best specificity – translates into burden reduction i.e. cost savings.